Ultimovacs announced it has completed treatment of the second dose cohort in the Phase I TENDU trial. The study is designed to evaluate the company’s tetanus-epitope targeting-platform in patients with prostate cancer.
[Ultimovacs]
Sorry, but the selected Zotpress account can't be found.
